Miles S, Magpantay L, Ellis C, Steihm R, Wong V, Selvaraj M, Hofheinz D; International Conference on AIDS.
Int Conf AIDS. 1991 Jun 16-21; 7: 222 (abstract no. W.B.2161).
UCLA AIDS Center, Los Angeles CA USA
OBJECTIVE: A new competitive immunoassay that quantifies the level of HIV p24 antibody (HIVp24Ab) is available. This assay may be useful in determining stage of disease, prognosis or response to therapy. Plasma infusions, which contain HIV p24 antibody, are used in passive immunotherapy. To determine if HIVp24Ab levels were altered by plasma infusions, we measured sequential serum HIV p24 antibody levels during multiple infusions of plasma over 8 months in 1 patient. METHODS: Serum was collected before each infusion and at least weekly after each treatment. Blood for quantitative plasma virus, lymphocyte limiting dilution and immune studies was simultaneously obtained. HIV p24 antigen and antibody levels were measured in batch on stored sera using the Coulter HIV p24 antigen and antibody assays as recommended. RESULTS: HIV p24 antigen was eliminated with therapy. Plasma infusions were accompanied by a rise in HIVp24ab. The magnitude of the rise in titer correlated with the antiviral effect as measured by plasma viremia titer. Infusions which failed to significantly increase HIV p24 antibody levels did not have a detectable plasma antiviral effect. TABULAR DATA, SEE ABSTRACT VOLUME. The half-life of HIV p24 antibody was 21 days initially and increased with successive courses of therapy. CONCLUSIONS: Quantitative HIV p24 antibody levels are a useful assay in monitoring patients receiving plasma infusions. The assay can be used to measure the half-life of infused HIV p24 antibody and may be useful in selecting donors with a greater plasma antiviral activity.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Antiviral Agents
- HIV Antibodies
- HIV Core Protein p24
- HIV Infections
- HIV Seropositivity
- Humans
- Plasma
- Viremia
- immunology
- organization & administration
Other ID:
UI: 102192765
From Meeting Abstracts